A Phase 2 trial involving mazdutide was updated on August 6, 2026, with a status of recruiting. The trial, registered as NCT06143956, is titled "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight."
The study uses a master protocol design, which allows multiple intervention-specific appendices to be evaluated under one overarching framework. It is enrolling adult participants who have obesity or are classified as overweight.
As of the August 6, 2026 update, the trial status remains recruiting. No results have been posted for this study as part of this update. The trial is registered at Phase 2 on ClinicalTrials.gov under the identifier NCT06143956.
Mazdutide remains classified as an unapproved compound under research investigation. This update reflects only the recruitment status and trial design details as listed in the registry entry. No efficacy or safety outcomes are described in this update.
Readers interested in mazdutide's broader research background can consult the compound overview for additional context.